AU738384B2 - Cationic reagents for transfection - Google Patents

Cationic reagents for transfection Download PDF

Info

Publication number
AU738384B2
AU738384B2 AU53156/98A AU5315698A AU738384B2 AU 738384 B2 AU738384 B2 AU 738384B2 AU 53156/98 A AU53156/98 A AU 53156/98A AU 5315698 A AU5315698 A AU 5315698A AU 738384 B2 AU738384 B2 AU 738384B2
Authority
AU
Australia
Prior art keywords
denotes
chained
alkyl
straight
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU53156/98A
Other languages
English (en)
Other versions
AU5315698A (en
Inventor
Christoph Erbacher
Martin Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qiagen GmbH
Original Assignee
Qiagen GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qiagen GmbH filed Critical Qiagen GmbH
Publication of AU5315698A publication Critical patent/AU5315698A/en
Application granted granted Critical
Publication of AU738384B2 publication Critical patent/AU738384B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU53156/98A 1996-11-04 1997-11-03 Cationic reagents for transfection Expired AU738384B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3031596P 1996-11-04 1996-11-04
US60/030315 1996-11-04
PCT/EP1997/006035 WO1998019709A2 (en) 1996-11-04 1997-11-03 Cationic reagents for transfection

Publications (2)

Publication Number Publication Date
AU5315698A AU5315698A (en) 1998-05-29
AU738384B2 true AU738384B2 (en) 2001-09-20

Family

ID=21853640

Family Applications (1)

Application Number Title Priority Date Filing Date
AU53156/98A Expired AU738384B2 (en) 1996-11-04 1997-11-03 Cationic reagents for transfection

Country Status (7)

Country Link
US (2) US6733777B2 (https=)
EP (1) EP1003556B1 (https=)
JP (1) JP4175667B2 (https=)
AU (1) AU738384B2 (https=)
CA (1) CA2270396C (https=)
DE (1) DE69735382T2 (https=)
WO (1) WO1998019709A2 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674908A (en) * 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
DE69735382T2 (de) * 1996-11-04 2006-11-30 Qiagen Gmbh Kationische reagenzien zür transfektion
DK1129064T3 (da) 1998-11-12 2008-04-28 Invitrogen Corp Transfektionsreagenser
CA2299119C (en) * 1999-02-23 2013-02-05 Qiagen Gmbh A method of stabilizing and/or isolating nucleic acids
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
US7906122B2 (en) 2003-06-18 2011-03-15 Yissum Research Development Company Of The Hebrew University Of Jersusalem Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination
MXPA05013746A (es) 2003-06-18 2006-06-27 Yissum Res Dev Co Conjugados de esfingoide-polialquilamina para vacunacion.
US20060211004A1 (en) 2005-02-15 2006-09-21 Ilsley Diane D Methods and compositions for determining non-specific cytotoxicity of a transfection agent
US20060257858A1 (en) * 2005-04-01 2006-11-16 Invitrogen Corporation Methods and compositions for introducing biopolymers into cells
EP2366787B1 (en) 2006-01-13 2019-12-11 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells
CA2686735A1 (en) 2007-05-04 2008-11-13 Mdrna, Inc. Amino acid lipids and uses thereof
CA2726187A1 (en) 2008-05-30 2009-12-23 Yale University Targeted oligonucleotide compositions for modifying gene expression
CN102231979B (zh) 2008-10-16 2014-10-29 玛瑞纳生物技术有限公司 基因沉默治疗剂的脂质体有效递送方法和组合物
HUE042177T2 (hu) 2009-12-01 2019-06-28 Translate Bio Inc Szteroidszármazék mRNS szállítására humán genetikai betegségekben
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
WO2011120023A1 (en) 2010-03-26 2011-09-29 Marina Biotech, Inc. Nucleic acid compounds for inhibiting survivin gene expression uses thereof
WO2011133584A2 (en) 2010-04-19 2011-10-27 Marina Biotech, Inc. Nucleic acid compounds for inhibiting hras gene expression and uses thereof
WO2011139843A2 (en) 2010-04-28 2011-11-10 Marina Biotech, Inc. Multi-sirna compositions for reducing gene expression
FR2964569B1 (fr) 2010-09-10 2012-10-19 Ct De Cooperation Internationale En Rech Agronomique Pour Le Dev Cirad Nouveaux liposomes de vaccination genique
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2012078667A2 (en) 2010-12-06 2012-06-14 The Penn State Research Foundation Compositions and methods relating to proliferative diseases
PL3586861T3 (pl) 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
ES2567091T3 (es) 2012-04-05 2016-04-19 F. Hoffmann-La Roche Ag Compuestos de amina para la preparación selectiva de muestras biológicas
EP3536787A1 (en) 2012-06-08 2019-09-11 Translate Bio, Inc. Nuclease resistant polynucleotides and uses thereof
PL3467108T3 (pl) 2013-03-14 2024-09-30 Translate Bio, Inc. Sposoby oczyszczania informacyjnego rna
KR20210122917A (ko) 2013-03-14 2021-10-12 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
AU2013381922A1 (en) 2013-03-15 2015-09-24 The Penn State Research Foundation Compositions and methods including leelamine and arachidonyl trifluoromethyl ketone relating to treatment of cancer
WO2014143031A1 (en) 2013-03-15 2014-09-18 The Penn State Research Foundation Compositions and methods including celecoxib and plumbagin relating to treatment of cancer
EA034103B1 (ru) 2013-10-22 2019-12-27 Транслейт Био, Инк. СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
ES2707966T3 (es) 2013-10-22 2019-04-08 Translate Bio Inc Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
PT3134506T (pt) 2014-04-25 2019-10-31 Translate Bio Inc Métodos de purificação de rna mensageiro
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
EA201991747A1 (ru) 2017-02-27 2020-06-04 Транслейт Био, Инк. НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
MX2019013752A (es) 2017-05-16 2020-07-20 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
CA3108544A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
MX2021005969A (es) 2018-11-21 2021-09-14 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado.
US20220175723A1 (en) 2019-04-22 2022-06-09 The Penn State Research Foundation Methods and compositions relating to inhibition of aldehyde dehydrogenases for treatment of cancer
CN114656422B (zh) * 2022-04-22 2023-05-23 重庆理工大学 一种新型氮杂冠醚化合物及其阳离子脂质体、制备方法与应用
US20230392188A1 (en) 2022-06-02 2023-12-07 Perkinelmer Health Sciences, Inc. Electrophoresis-mediated characterization of dna content of adeno-associated virus capsids

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966630A (en) * 1972-03-24 1976-06-29 Petrolite Corporation Use of polyquaternary ammonium methylene phosphonates in chelating or scale inhibition
US4022833A (en) * 1973-02-14 1977-05-10 Sterling Drug Inc. N,N'-bridged-bis[2-alkyl-2-hydroxyethylamines]
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5220454A (en) * 1990-03-30 1993-06-15 Nikon Corporation Cata-dioptric reduction projection optical system
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
DE19505368A1 (de) * 1995-02-17 1996-08-22 Huels Chemische Werke Ag Amphiphile Verbindungen mit mindestens zwei hydrophilen und mindestens zwei hydrophoben Gruppen auf der Basis von Dicarbonsäurediamiden
CA2214029A1 (en) * 1995-04-25 1996-10-31 Magda Marquet Single-vial formulations of dna/lipid complexes
US5744335A (en) * 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US5780448A (en) * 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
DE69735382T2 (de) * 1996-11-04 2006-11-30 Qiagen Gmbh Kationische reagenzien zür transfektion

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS V110 NO.3 ABS. NO. 20127 *
CHEMICAL ABSTRACTS V115 NO. 25 ABS. NO. 275625 *

Also Published As

Publication number Publication date
US20040077582A1 (en) 2004-04-22
US20010048939A1 (en) 2001-12-06
AU5315698A (en) 1998-05-29
CA2270396A1 (en) 1998-05-14
EP1003556B1 (en) 2006-03-01
WO1998019709A2 (en) 1998-05-14
DE69735382D1 (de) 2006-04-27
JP4175667B2 (ja) 2008-11-05
DE69735382T2 (de) 2006-11-30
WO1998019709A3 (en) 1998-07-30
JP2001503751A (ja) 2001-03-21
US6733777B2 (en) 2004-05-11
EP1003556A2 (en) 2000-05-31
CA2270396C (en) 2008-03-11

Similar Documents

Publication Publication Date Title
AU738384B2 (en) Cationic reagents for transfection
US5753613A (en) Compositions for the introduction of polyanionic materials into cells
JP3525393B2 (ja) 脂質及び例えばリポソーム中でのその使用
EP0814777B1 (en) Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) Stable lipid-comprising drug delivery complexes and methods for their production
DE69131347T2 (de) Kationische lipide für die intrazelluläre abgabe von biologisch aktiven molekülen
DE69527206T2 (de) Mittel zum einbringen polyanionischer materialien in zellen
EP1156783B1 (en) Encapsulation of bioactive complexes in liposomes
AU710170B2 (en) Cationic virosomes as transfer system for genetic material
JPH10501822A (ja) トランスフェクション剤、ワクチンアジュバントまたは薬剤としてのカチオン性両親媒性化合物の使用
JP2002542341A (ja) カチオン性ｐｅｇ脂質および使用方法。
HUP0203117A2 (hu) Semleges kationos lipid nukleinsav és hatóanyag szállítására
Huang et al. Bioresponsive liposomes and their use for macromolecular delivery
CN120615011A (zh) 脂质组合物及用于递送到免疫细胞的方法
Elsabahy et al. Dicationic gemini nanoparticle design for gene therapy
Sorgi et al. Drug delivery applications
JP2003522203A (ja) 天然に存在しない核酸組成物、核酸を細胞中にトランスフェクションするのに有用な処方物の調製のためのそれらの使用、および応用
AU770607B2 (en) Complex for transferring an anionic substance of interest into a cell
MXPA01008804A (en) Encapsulation of bioactive complexes in liposomes
MXPA01008802A (en) Heat-curable, thermally expandable moulded part

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)